Fifty-five hospitals located throughout twenty-one states have agreed to pay the United States a total of more than $34 million to settle allegations that the health care facilities submitted false claims to Medicare for kyphoplasty procedures. Kyphoplasty is a...
General Electric Aviation Systems (GEAS) agreed to pay $6.58 million to settle allegations that it submitted false claims in connection with multiple Department of Defense contracts. GEAS, headquartered in Ohio, manufactures and sells integrated systems and...
American Commercial Colleges, Inc. (“ACC”) has agreed to pay up to $2.5 million to resolve allegations that it violated the False Claims Act by falsely certifying that it complied with certain eligibility requirements of the federal student aid programs. In order to...
Science Applications International Corporation (SAIC) has agreed to pay $11.75 million to resolve a False Claims Act lawsuit alleging that it charged inflated prices under grants to train first responder personnel to prevent and respond to terrorist attacks. Between...
TesTech, Inc., CESO Testing Technology, Inc., CESO International, LLC, and CESO, Inc. have agreed to pay $2,883,947 to resolve allegations that they falsely claimed disadvantaged business status on a number of federally-funded transportation projects. The Department...
ISTA Pharmaceuticals, Inc. has pled guilty to felony charges relating to its marketing of Xibrom, an anti-inflammatory drug that was approved by the FDA to treat pain and inflammation following cataract surgery. The criminal charges arise from violations of the Food,...
U.S. Renal Care has agreed to pay $7.3 million to resolve a whistleblower lawsuit alleging that it overcharged the Medicare program for Epogen administered to dialysis patients at facilities operated by Dialysis Corporation of America (DCA). U.S. Renal Care acquired...
C.R. Bard Inc. has agreed to pay $48.26 million to resolve allegations that it knowingly caused false claims to be submitted to the Medicare program for brachytherapy seeds used to treat prostate cancer in violation of the False Claims Act. This case was initiated by...
Ranbaxy USA Inc., a subsidiary of Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited, pleaded guilty to charges relating to the manufacture and distribution of adulterated drugs made at two of its facilities. In addition to its guilty plea,...
In a settlement recently announced by the Department of Justice, Adventist Health System/West, d/b/a Adventist Health, and White Memorial Medical Center have agreed to pay the United States and the State of California $14.1 million to resolve allegations raised in a...
The Office of Inspector General (“OIG”) of the United States Department of Health and Human Services recently updated its Provider Self-Disclosure Protocol, which establishes a procedure for health providers to voluntarily disclose instances of potential fraud...
Amgen Inc. has agreed to pay $24.9 million to resolve a whistleblower lawsuit filed under the qui tam provisions of the False Claims Act. The allegations in this case relate to Amgen’s business practices concerning the sale of Aranesp, a pharmaceutical product. Based...